
ORKA Stock Forecast & Price Target
ORKA Analyst Ratings
Bulls say
Oruka Therapeutics is attractive because ORKA-001 has shown unusually strong and repeatable psoriasis efficacy, with 61% PASI 100 at 16 weeks in EVERLAST-B versus 63.5% in EVERLAST-A, while remaining clean on safety and supporting advancement of the 600mg dose into Phase 3. Its ~100-day half-life, more than 3x Skyrizi’s, creates a credible path to Q6M to Q12M maintenance dosing, which could materially reduce injection burden and improve commercial adoption in a market where efficacy still drives share. Financially, the company ended 3Q26 with $1.2 billion in cash and equivalents, guiding that this should fund operations through an ORKA-001 BLA filing, while ORKA-002 and ORKA-004 add pipeline breadth and option value.
Bears say
Oruka Therapeutics is a high-risk clinical-stage biotech with no commercial revenue, so its valuation depends heavily on successful development and eventual approval of ORKA-001 and ORKA-002. The investment case is weakened by meaningful regulatory uncertainty, including the possibility of regulators demanding additional or longer studies, changing approval standards, or limiting product labels in ways that reduce market traction. Financially, the company still needs to access capital markets to fund development and commercialization, and any clinical delays, trial failures across PsO, HS, or other indications, unexpected safety issues, or stronger competing longer-acting mAb therapies could materially pressure the stock.
This aggregate rating is based on analysts' research of Oruka Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ORKA Analyst Forecast & Price Prediction
Start investing in ORKA
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Oruka Therapeutics Inc (ORKA) Forecast
ORKA Analyst Forecast & Price Prediction
Start investing in ORKA
Order type
Buy in
Order amount
Est. shares
0 shares